<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04249674</url>
  </required_header>
  <id_info>
    <org_study_id>2019-01418</org_study_id>
    <nct_id>NCT04249674</nct_id>
  </id_info>
  <brief_title>Impact of CYP2D6 Genetic Polymorphisms on the Vulnerability to Drug-drug Interactions With Tramadol</brief_title>
  <acronym>PREDICT</acronym>
  <official_title>Impact of CYP2D6 Genetic Polymorphism on the Vulnerability to Drug-drug Interactions With Tramadol: a Gene-environment Interaction and Phenoconversion Study on Patients Undergoing a Steady Treatment With a Potent CYP2D6 Inhibitor.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Youssef Daali</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jules Desmeules</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kenza Abouir</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eduardo Schiffer</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bernard Walder</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Geneva</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite its poor abundance in the liver, CYP2D6 is the second most important CYP in drug
      metabolism, metabolizing 20% of drugs. The high inter-individual variability in CYP2D6
      expression is explained by genetic variations, but also by drug-drug interactions (DDIs).
      Recent studies have pointed out the poor therapeutic predictable value of DDI. Indeed, the
      clinical outcomes of a DDI may involve several intrinsic factors affecting the vulnerability
      to and extent of DDI, such as genetic polymorphisms, comorbidities, age and sex.

      In this regard, the present research project aims to investigate the effect of genetic
      polymorphism on DDIs involving CYP2D6 (gene-environment interaction) and its implications for
      tramadol efficacy and safety in a clinical setting. In a previous study, we demonstrated
      differences in both the rate of phenoconversion and the magnitude of DDI in healthy
      volunteers, that were either heterozygote normal metabolizers (NMs) carrying a non-functional
      CYP2D6 allele (activity score (AS) 1) and homozygous NM carrying two fully-functional CYP2D6
      alleles (AS 2).

      This prospective study will include patients scheduled for a general surgery of less than 3
      hours and planned to be treated with oral tramadol as a routine post-operative pain
      management.

      Patients taking part in the study may receive diagnosis, therapeutic or other interventions
      but the groups of individuals (controls vs inhibited) are predefined based on the routine
      treatment of the patients.

      There will be no assigned specific interventions to the study participants and CYP2D6
      phenotypes will be classified in five activity score groups (0.5, 1, 1.5, 2, &gt;2) in the
      absence or presence of a potent CYP2D6 inhibitor received as part of routine medical care.

      PK of tramadol and its active metabolite (M1), as well as its analgesic and PD effects and
      safety, will be compared between groups. Finally, the data generated will be used to build a
      physiologically-based PK (PBPK) model for tramadol in different sub-groups. The model will
      aim to predict the effect of CYP2D6 inhibition in virtual populations with different
      genetically-related CYP2D6 activities. This should allow prospective dose adjustment of
      tramadol (or appropriate drug selection) based on patients' genotype in the presence of a
      CYP2D6 inhibitor.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 4, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the proportion of patients in each group who acquires a phenotype switch (phenoconversion) with or without CYP2D6 inhibitor.</measure>
    <time_frame>10 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of Tramadol , Dexrometorphan and their metabolites maximum plasma concentration (Cmax) according to patient belonging to the control or inhibited group.</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Tramadol, Dextrometorphan and their metabolites Area Under the curve (AUC) according to patient belonging to the control or to the inhibited group and to his CYP2D6 phenotype</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Tramadol, Dextrometorphan and their metabolites Clearance (CL) according to patient belonging to the control or to the inhibited group.</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Urinary metabolic ratio (UMR) tramadol/M1 in urine collection</measure>
    <time_frame>8 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Saliva metabolic ratio tramadol/M1</measure>
    <time_frame>2 hours</time_frame>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">172</enrollment>
  <condition>Interaction</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Patient under a CYP2D6 inhibitor and under Tramadol</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient not under a CYP2D6 inhibitor but under Tramadol</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Dextrometorphan</intervention_name>
    <description>Administration of 4 ml=10 mg of Dextrometorphan (Bexine sirup)</description>
    <arm_group_label>Patient not under a CYP2D6 inhibitor but under Tramadol</arm_group_label>
    <arm_group_label>Patient under a CYP2D6 inhibitor and under Tramadol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Genotyping by single nulcetoide polymorphism.</intervention_name>
    <description>Single nucleotide polymorphism determination</description>
    <arm_group_label>Patient not under a CYP2D6 inhibitor but under Tramadol</arm_group_label>
    <arm_group_label>Patient under a CYP2D6 inhibitor and under Tramadol</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Biological fluids : blood, urine and saliva
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be recruited through a pre-surgery anesthetic evaluation visit. During their
        scheduled visit with an anaesthesiologist, potential patients will be invited to
        participate to an information session where project aim and design, procedures involved,
        expected duration as well as possible risks will be explained in details.

        After sufficient time of reflection, volunteers willing to participate in the study will
        sign the consent form.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any male and female patients &gt; 18 years scheduled for a surgery of less than 3 hours
             duration and planned to be treated with oral tramadol as a routine management of
             post-operative pain;

          -  Patients with physical conditions classified as ASA I to III, based on American
             Society of Anesthesiology classification;

          -  Patients treated chronically with a potent CYP2D6 inhibitor (for CYP2D6-inhibited arms
             only);

          -  Understanding of French language and able to give a written inform consent

        Exclusion Criteria:

          -  Pregnant or breastfeeding woman

          -  Any pathologies, use of drugs or food that may affect CYP activity (for control arms
             only and based on the 'drug interactions and cytochromes P450' table published by The
             Service of clinical Pharmacology and Toxicology [3], HUG and on the investigator's
             knowledge)

          -  Liver transplantation history

          -  Sensitivity to dextromethorphan (CYP2D6 probe drug) or any contra-indication to
             dextrometorphan

          -  Medical history of cirrhosis (Child Pugh B and C) or/and hepatosteatosis.

          -  Glomerular filtration rate (GFR) &lt; 30 ml/min/1.73m2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Youssef Daali, Pr.</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Geneva</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Caroline Samer, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Geneva</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Caroline Samer, Doctor</last_name>
    <phone>022 372 99 47</phone>
    <email>caroline.samer@hcuge.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Geneva University Hospitals, HUG</name>
      <address>
        <city>Gen√®ve</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Samer, Dr</last_name>
      <email>caroline.samer@hcuge.ch</email>
    </contact>
    <contact_backup>
      <last_name>Kenza Abouir</last_name>
      <email>kenza.abouir@hcuge.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 4, 2019</study_first_submitted>
  <study_first_submitted_qc>January 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2020</study_first_posted>
  <last_update_submitted>January 29, 2020</last_update_submitted>
  <last_update_submitted_qc>January 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Geneva</investigator_affiliation>
    <investigator_full_name>Caroline Samer</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>Cytochrome</keyword>
  <keyword>Polymorphism</keyword>
  <keyword>Genotyping</keyword>
  <keyword>Phenotyping</keyword>
  <keyword>Tramadol</keyword>
  <keyword>CYP2D6 inhibitor</keyword>
  <keyword>Phenoconversion</keyword>
  <keyword>Environment</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

